With this news it could get interesting today?
$Innate Pharma(IPHA.US$ Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform
Sanofi (SNY) has exercised its option to license its fourth natural killer cell engager program in solid tumors from Innate Pharma's (IPHA) Antibody-based NK Cell Engager Therapeutics, or ANKET, platform, according to a Tuesday statement.
The ANKET is Innate's platform for developing multi-specific natural killer cell engagers to treat certain types of cancer.
Sanofi, which will be responsible for all development, manufacturing and commercialization of the program following a research collaboration period, also retains the option to one additional ANKET target, the companies said.
Under an agreement signed by the companies in December 2022, Innate will receive 15 million euros ($16.4 million) as option exercise payment. It is also eligible for up to 1.35 billion euros in preclinical, clinical, regulatory and commercial milestones, as well as royalties on potential net sales.![]()
Sanofi (SNY) has exercised its option to license its fourth natural killer cell engager program in solid tumors from Innate Pharma's (IPHA) Antibody-based NK Cell Engager Therapeutics, or ANKET, platform, according to a Tuesday statement.
The ANKET is Innate's platform for developing multi-specific natural killer cell engagers to treat certain types of cancer.
Sanofi, which will be responsible for all development, manufacturing and commercialization of the program following a research collaboration period, also retains the option to one additional ANKET target, the companies said.
Under an agreement signed by the companies in December 2022, Innate will receive 15 million euros ($16.4 million) as option exercise payment. It is also eligible for up to 1.35 billion euros in preclinical, clinical, regulatory and commercial milestones, as well as royalties on potential net sales.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
